Saturday - April 25, 2026
Imaavy Shows Over Two Years of Sustained Disease Control in a Broad Population With Generalized Myasthenia Gravis
April 23, 2026
RARITAN, New Jersey, April 23 -- Johnson and Johnson Innovative Medicine issued the following news release on April 22, 2026:

* * *

IMAAVY(R) (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)

Through 120 weeks of follow-up, IMAAVY delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including anti-AChR+ and anti-MuSK+
. . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products